MTCH 24

Drug Profile

MTCH 24

Alternative Names: MTCH-24; Zilex; Zorex

Latest Information Update: 16 Sep 2015

Price : $50

At a glance

  • Originator Meditech Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne; Herpes simplex virus infections

Most Recent Events

  • 17 Jun 2002 Phase-I/II clinical trials in Herpes simplex virus infections in USA (Topical)
  • 15 Jun 2001 Preclinical development for Acne in USA (Topical)
  • 23 Mar 2000 MTCH 24 has been licensed to Immune Network Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top